Regeneron seeks to edge Roche out of DME space

Share this article:
Eylea outduels Lucentis for physician mindshare, survey shows
Eylea outduels Lucentis for physician mindshare, survey shows

A year after its eye drug Lucentis landed the FDA's approval for diabetic macular edema, Roche's hold on this Eylea-free zone of the market may soon be ending. Regeneron, Eylea's manufacturer, said Tuesday that it expects to submit an NDA for this very same indication to the FDA this year, while its European marketing partner, Bayer, is on track to do the same abroad.

This would mean more than a me-too in the diabetic macular edema (DME) space. As noted by Forbes, Lucentis has a downside in that its label has a fatality warning. Eylea's does not, and that could give the Regeneron drug an edge if it too gets approved for use in DME.

It's not the first threat to Lucentis' hold on the eye market. The wet macular-degeneration drug saw immediate competition from off-label use of Genentech's Avastin, then from macular-degeneration newcomer Eylea.

DME is linked to blurry vision and even blindness, and estimates say it affects about 560,000 Americans.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.